i\uthor Index

Anderson, Robert J. 8-28 Borchardt, Ronald T 55-73 Bourque, M. 175-185 Branczyk-Kazma, Anna 55-73 Buu, Nguyen T. 145-151,175-185 Carter, Susan M. Bonham 186-206 Cesura, Andrea M. 44-54 Da Prada, Mose 44-54 Galva, Maria D. 44-54 Glover, Vivette 98-126,186-206 Halsema, Ina C.M. 86-97 Harnet, P. 175-185 Hammond, Donna L. 152-163 Kettler, Rolf 44-54 Koster, Henk 86-97 Kuchel,Otto 145-151,175-185 Larochelle, P. 175-185 Lockwood, Julia 186-206 Meerman, H N. 86-97 Montegazza, Prola 44-54 Mulder,Gerard J. 86-97,127-144 Pang, K. Sandy 86-97 Penninings E. J. M. 29-43 picotti, Giovanni 44-54 Pinnick, Carol L. 55-73 Rein, Glen 98-126,186-206 Renskers, Kevin 74-85 Rivett, Jennifer 74-85 Rorie, Duane K. 152-163

Roth, Jerome A. 74-85 Sandler,Merton 1-7,98-126,186-206 Sharpless, Nansie S. 164-174 Schasteen, Charles S. 55-73 Tabaddor, Karnran 164-174 Thal, Leon J. 164-174 Tyce,Gertrude M. 152-163,164-174 Van Brussel, J. L. 29-43 Van Kempen, G. M. J. 29-43 Waltz, Joseph M. 164-174 Weinshilbourn, Richard M. 8-28 Wolfson, Lelie I. 164-174 Yaksh, Tong L. 152-163 Zanen, J. G. 29-43

207

Subject Index

SUBJECT INDEX

acetaminophen (= paracetarno1) & PST 8 as sulfate acceptor 24,135-137

comparison with MHPG 24 as su1fation inhibitor 92-94

"active sulfate" - cf PAPS adenosine diphosphate (ADP)

& sulfate transfer 133 adenosine 5'-phosphosu1fate (APS)

in sulfate transfer 2,133 adenosine triphosphate (ATP)

& sulfate transfer 2 S-adenosy1methionine (SAM) (SAMe)

as enzyme cofactor 81 as methyl donor 147

radio labelled 165 adrenal PST

activity 101,177 kinetics 112 M vs P form 115 substrate

ratios 111 specificity 107,110,111

adrenaline (A) - cf epinephrine affinity chromatography

of PST 70 aldosteronism, primary

& su1foconjugation 182 alkyl alcohols

& su1fotransferases 1

208

allyl alcohols & sulfotransferases 1

amines (also cf specific compounds) conjugated

efflux into superfusates 152-163 antipsychotic drugs (also cf specific compounds)

& HVA levels 170 APS-kinase (= ATP-adenylyl sulfate 3'-phosphotransferase EC

2.7.1.25) 2 lack of multiple forms 137 in sulfate transfer 2,133

arginine in PST active site 65

arylsulfatase in thrombocytes 33,39

ascites tumor sulfate uptake 133

assay of sulfoconjugated monoamines 50 of PST 8-28,56,71

& BSA 18 & dithiothreitol 18 in intestine 16-20 in kidney 16-20 in platelet 16-20 technique 9-10,31

ATP-adenylyl sulfate 3'-phosphotransferase -cf APS-kinase ATP sulfurylase

lack of multiple forms 139 in sulfate transfer 2,133

benzylamine oxidase multiple forms 100

benzyrene sulfation inhibition by salicylamide 92

blood density gradient centrifugation 31-32,33-37

blood-brain barrier crossing

by DCNP 91 by MOPEG 149 by PCP 91

non-crossing by MOPEG-S04 149

blood cells (also cf erythrocytes and other cell types) differential destruction 39

bovine serum albumin (BSA) & PST assay 18

brain (also cf specific areas) absence of PAPS 133 CA sulfates 147

209

210 postmortem 100 PST 3,4,29,101,177

activity in various regions 147 characterization 55-73,74-85 & inhibitors 14 kinetics 112 M vs P forms 115 & neurotransmitter inactivation 74 purification 55-73 substrate ratio specificity III substrate specificity 69,107,111 from various species 55

sulfate uptake 131-133

calcium availability & sulfate 137

carbohydrates & sulfotransferases 1

carcinogenesis as a result of sulfation 86

catecholamines (CA) (also cf individual compounds) methoxy derivatives

& sulfoconjugation 47-48 sulfates 37,45-46,74,145-151

assay 147 in brain 147 & hypertension 175-185 & PST 145-151,175-185

sulfation & resistance to COMT 145 & resistance to MAO 145 & stability 145

catechol O-methyltransferase (COMT) assay 75 & DA inactivation 79-83 & neurotransmitter inactivation 74 in platelets 44 stability

after sulfation 145 cerebellum

PST activity 117,147 DA

E

NE

free 147 sulfate 147

free 147 sulfate 147

free 147 sulfate 147

cerebrospinal fluid (CSF) (also cf ventricular fluid)

DA-S04 152 from periphery 152

PST 3 chlorimipramine

& NMN uptake 48 E-chloroamphetamine (peA)

& spinal cord 5-HIAA 161-162 5-HT 161-162

clorgyline & DA-S04 152 MAO inhlbition 154,157-159 structure 152

cocaine & NMN uptake 48

cortex DA

E

NE

free 147 sulfate 147

free 147 sulfate 147

free 147 sulfate 147

PST 147 cysteine

& glutathione 134 & protein synthesis 134 & sulfate conjugation 2 & sulfate levels 134 as sulfate source 128,129,131-132

genetic problems 129 mechanism 129

& taurine 134 cystine

& sulfate conjugation 2

defibrination & MAO 37-38,39 & PST 37-38,39

depression & tyramine sulfation 40,192-197

detoxification & conjugation enzymes 86-87

dexamethasone & PST activity 182

diet & sulfate 135,138

dibromsu1phalein (DBSP) excretion 88

211

212 2,6-dichloro-4-nitrophenol (DCNP) & blood-brain barrier 91 & NMN uptake 48 selective inhibition of PST forms 98 as sulfation inhibitor 65,70,88-91,l09,ll3,1l4

& harmol sulfation 90 & hydroxamic acid sulfation 9l reversibility 90

toxicity 91-92 3,4-dihydrobenzoic acid

as sulfate acceptor 33 3,4-dihydroxymandelic acid (DOMA)

as PST substrate 67,103 specificity 69

3.4-dihydroxyphenylacetic acid (DOPAC) as PST substrate 67,76,101,103

specificity 69,101 structure 104

3,4-dihydroxyphenylglycol (DHPG) as PST substrate 67,102,104

specificity 69 structure 104

3,4-dihydroxyphenylalanine (Dopa) methylation 9 as PST substrate l03

2,6~imethyl-4-nitrophenol

& inhibition of harmol sulfation 90 dithiothreitol

& PST assay l8,32 dopamine (DA)

assay 155-l56/165 comparison of techniques l66-l68

conjugated inventricular fluid 164-l74 vs free 4

inactivation, by PST 79-83 & platelet PST l06,l77,l87-l88

kinetics 106 platelet uptake 47 & PST 45-46

from various tissues l07-108 as PST substrate 76,l02,l04

for various tissues lOl specificity 69

release into ventriculo-cisternal perfusates l57-l60 structure 104 3-0-sulfate vs 4-0-sulfate 39 as sulfate acceptor 2

comparison with MHPG 23 sulfation, in vitro 75

in various brain regions 147 dopamine S-hydroxylase (DBH) (DSH)

DA-3-0-sulfate as substrate 145-146 DA-4-0-sulfate as substrate 145-146

dopamine sulfate (DA-S04 ) assay 155-156 3-0 vs 4-0 , as DBH substrates 145 in Parkinsonism

in CSF 75 in plasma 74 in platelets 50

40,75

release in CNS 152,157-159 as transport form 4 in various brain regions 147

drugs (cf also classes of drugs and sulfation 138

epinephrine (E)

individual drugs)

after hydrolysis of conjugated E 176 & platelet PST 177

kinetics 106 platelet uptake 47 & PST 45-46 as PST substrate

specificity structure 104 sulfate

in platelets

76,102,104 69

50 in various brain regions 147

sulfation 3 & pressor activity 75 in vitro 75

in various brain regions 147 erythrocytes (RBC)

COMT

PST genetic control 8

assay 11 & endogenous inhibitors 11-16 properties 11-12 purification 10,11

quantitation 31 sulfate uptake 133

ethacrynic acid glutathione conjugation 34

N-ethylmaleimide & NMN uptake 48

fasting & sulfate 130

frontal cortex PST activity 101,117

213

214 M vs P forms 116

genetic control of RBC COMT 8 of sulfate formation 129

glucocorticoid sulfation & hypertension 145

glucuronidation as competitor of sulfation 87,88-89,135 of harmol 88-89

glutathione & cysteine administration 134

glycolipids & sulfotransferases 1

glycosaminoglycans as sulfate source 128

harmol conjugation 88 glucuronidation 93 structure 88 sulfation 88-91

inhibition by various drugs 90,93-94 headache (also cf migraine)

& PST 202-203 heart

PST 148,177 hepatocytes

& sulfation 139 hippocampus

DA

E

NE

free 147 sulfate 147

free 147 sulfate 147

free 147 sulfate 147

PST activity 117,147 homovani1lic acid (HVA)

& antipsychotic drugs 170 in CSF 164 ss PST substrate 67,102

specifici ty 69 structure 104

homovanillic alcohol as PST substrate 67

specifici ty 69 hydrolysis

of conjugated CA 175-176 comparison of methods 175-176

hydroxamic acids (also cf specific compounds) su1fation inhibition

by DCNP 91 by PCP 91

N-hydroxy-2-acety1aminof1uorene hepatotoxic effect

& su1fation 91 su1fation 86

inhibition by DCNP 91 inhibition by PCP 91

£-hydroxybenza1dehyde as PST substrate 67

specificity 69 5-hydroxyindo1eacetic acid (5-HIAA)

assay 156-157 as PST substrate 103

4-hydroxy-3-methoxymande1ic acid (VMA) & platelet PST kinetics 106 & PST from various tissues 107-108 as PST substrate 102,104 structure 104

4-hydroxy-3-methoxypheny1ethano1 (HMPE) as PST substrate 102,104 structure 104

4-hydroxyphenacetin su1fation inhibition

by DCNP 91 by PCP 91

l'-hydroxysaffro1e su1fation 86

5-hydroxytryptamine - cf serotonin hypertension

& CA sulfates 175-185 & glucocorticoid su1fation 145 & platelet PST 175-185

hypothalamus DA

E

NE

free 147 sulfate 147

free 147 sulfate 147

free 147 sulfate 147

PST 147

inhibitors of PST (also cf specific compounds) endogenous 8-28 properties 14 & PST assay 9 in vivo 86-97

215

216 intestine biopsy 9 PST

assay 16-20 & inhibitors 14 of kidney 25 of platelet 25

isopreno1ine & PST from various tissues 107-108,110 as PST substrate 102,104 structure 104

jejunum PST activity 101,177 kinetics 112 M vs P form 115 substrate ratios 111 substrate specificity 107,111

kidney biopsy samples 9 COMT

& RBC COMT 8 PST 148,177

assay 16-20

kinetics

& inhibitors 13-i4 & intestine PST 25 & platelet PST 25 substrate specificity 69

of platelet PST 105-109 of su1fation 139

laxative effect of sulfate 129

liver

lung

PST 148,177 & inhibitors 14 substrate specificity 69 from various species 55

cancer glucuronidation vs su1fation 119

COMT & RBC COMT 8

PST 177 lymphocyte COMT

& RBC COMT 8

metadrena1ine - cf metanephrine metanephrine (MN)

platelet uptake 47 as PST substrate 45-46,102,104

specificity 69 structure 104

methionine as sulfate source 128

3-methoxy-4-hydroxyphenylethyleneglycol (MOPEG) as PST substrate 146

3-methoxy-4-hydroxyphenylglycol (MHPG) & platelet PST kinetics 106 & PST

from various tissues 107-108,110 as PST substrate 67,76,102,104,187-188

specificity 69 structure 104 sulfate

as sulfation product 10,12,19-20 as sulfate acceptor 10,55

comparison with DA 23 comparison with 5-HT 24 comparison with MU 32-33,39 comparison with various compounds 24 & human platelet PST 29-43

3-methoxytyramine (MT) & platelet PST kinetics 106 platelet uptake 47 & PST 45-46 as PST substrate 76,102,104 structure 104

methylation vs sulfation 87

a-methyldopa as sulfate acceptor 55

comparison with MHPG 24 & sulfate conjugation by PST 8

a-rnethyldopahydrazine as Dopa decarboxylase inhibitor 152

3-methyl-2-nitrophenol & inhibition of harmol sulfation 90

4-methylurnbelliferone (MU) as PST substrate 31-43

comparison with MHPG 32-33,39 migraine

& platelet PST 200-203 tyramine-sensitive 145

monoamines (also cf specific compounds) sulfoconjugation 44-54

monoamine oxidase (MAO) assay 31,75 & defibrination 37-38 & inactivation of neurotransmitters 74,79-83 multiple forms 100 in platelets 44

217

218 vs PST in intestine 122 in platelet 122

stability, after sulfation 145 as thrombocyte marker 33

I-naphthol sulfation inhibition by DCNP 88

neuroblastoma PST activity 119 substrate ratios III substrate specificity 110

neurotransmitters (also cf specific compounds) inactivation

by COMT 74 by MAO 74 by PST 74

e-nitrophenol as PST substrate 64,67

inhibition by DCNP 88 specificity 69

noradrenaline - cf norepinephrine norepinephrine (NE)

& platelet PST 106,177 kinetics 106

platelet uptake 47 as PST substrate 76,102,104

specificity 69 from various tissues 107-108,110

structure 104 sulfate 74

assay 165 after hydrolysis of conjugated NE 176 in platelets 50

in various brain regions 147 normetadrenaline - cf normetanephrine normetanephrine (NMN)

platelet uptake 47,49 as PST substrate 45-46,76,102,104

specificity 69 structure 104 sulfate

in platelets 50 & sulfoconjugation efficacy 49 uptake and conjugation

effect of various compounds 48,49

!!!.-octopamine as PST substrate 102,104 structure 104

e octopamine as PST substrate 69,102,104

structure 104 sulfate

absence from platelets 50 ouabain

& NMN uptake 48 oxidative phosphorylation

uncoupling by PCP 92

pancreas PST activity 177

Parkinson's disease & HVA

in caudate nucleus 164 in ventricular CSF 164

Parkinsonism & DA-SO 40 & p1ate1et PST 197-200

permeability & su1fation 145

paracetamo1 - cf acetaminophen pentachlorophenol (PCP)

as PST inhibitor 88-91,109 of harmol 90 of hydroxamic acids 91

toxicity 91,·92 uncoupling of oxidative phosphorylation 92

phaeochromocytoma PST

M vs P form 115,118 substrate ratio III substrate specificity 110

& su1foconjugation 181 phenol

& platelet PST kinetics 106 as PST substrate 102,104 & PST from various tissues 107-108,110 structure 104 sulfate

stability 3 & su1fation 1,88,98,135,188

inhibition by DCNP 88 phenolic steroids

& su1fotransferases 1 phenolphthalein

glucuronidation 88 phenolsu1fotransferase (PST) (EC 2.8.2.1)

action 55 in various tissues 176-177

arginine in active site 65 assay 56,71,75,100,186 biochemical characterization 75-79

219

220 brain 3,4 action 56 characterization 55-73,74-85 & various substrates 69

& CA sulfates in rat brain 145-151 characterization 55-73 conformational changes 1 & defibrination 37-38 distribution 3 functional role 4 gel electrophoresis 57 & inactivation of neurotransmitters 74,79-83 inhibition

by 2,6-dichloro-4-nitrophenol 70 by phenylglyoxal 70-71

in jejunum 146 kidney

& various substrates 69 kinetics 4,146 liver

& various substrates 69 vs MAO 122

in intestine 122 in platelet 122

M form 98-127 kinetic studies 189-190

molecular weight 56-57,70 multiple forms 4,98-126

in rats 120 & neurotransmitter function 8 & PAPS substrate inhibition 30 P form 98-127

vs M form 186 platelet 3,4,8-28,146

assay 8-28 clinical studies 186-206 endogenous inhibitors 8-28 & MHPG sulfation 29-43

purification 55-73,70,77-79 by affinity chromatography 70

rat vs human 99

RBC

purification 10 in renal cortex 146 role in tissues 146 separation from steroid sulfotransferase 99 specific, for DOPAC 101 stability 190-192

therrnostability 191-193 & stereoselectivity 40

& sulfate conjugation of various drugs 8 in various organs 99

phenolsulphokinase misidentification of PST 3

phenylethylamine as PST substrate 103

phenylglyoxal inhibition of PST 70 71

phenyl sulfate from phenol 98

3'-phosphoadenosine-5'-phosphate (PAP) in sulfate transfer 2

3'-phosphoadenosine-5'-phosphosulfate (PAPS) as "active sulfate" 2 brain

absence of 133 presence of 169

cellular concentration in rat liver 133 contamination by 3,5'-biphosphate 30 intracellular pool 139 preparation 30 & PST substrate inhibition 30,89 radio labelled

in PST assay 146 sulfate

in synthesis 127,133 in sulfate transfer 2,100,137 synthesis 139-140

as sulfation limiting 140 phospholipids

sulfation 86 pituitary PST

& inhibitors 14 placenta PST

activity 101 kinetics 112 M vs P form 115 substrate ratios III substrate specificity 107,111

platelet(s) COMT 44 endogenous su1foconjugated monoamines 50-51 isolation 9,30 MAO 44 & monoamine su1foconjugation 44-54 PST 3,4,8-28,29-43,44-54,100-109,177

assay 16-20,21 assay variability 21-23 & CA sulfates 175-185 characteristics 20-23 clinical studies 186-206

221

222 & DCNP inhibition 113 function 4 & hypertension 175-185 & intestine PST 25 & kidney PST 25 kinetics 33,45-46,105 107,112 M vs P form 115 MHPG su1fation 29-43 storage effects 20 substrates 100-105 substrate ratios III substrate specificity 107,111 substrate & tissue correlations 23-25

procainamide ethobromide (PAEB) acetylation 88

protein assay 32 in diet

& sulfate 138 su1fation 86,128 synthesis

& cysteine administration 134 putamen

PST activity 117 pyrogallol

& NMN uptake 48

"radiosu1fate space" definition 127

reserpine & NMN uptake 48

salicylamide & inhibition of harmo1 su1fation 90,92 as PST substrate 67

specificity 69 & sulfate conjugation as su1fation inhibitor

serotonin (5-HT)

3,55,135 92-94

& conjugate 152-163 assay 156-157

& platelet PST kinetics platelet uptake 47 & PST 45-46,102,106

specificity 69 from various tissues

release from spinal cord sulfate

in platelets 69 as sulfate acceptor

comparison with MHPG

106

107-108,llO 161-162

24

sodium fluoride (NaF) & NMN uptake 48

sodium sulfate & NMN uptake 48

spinal cord & release

of 5-HIAA 161-162 of 5-HT 161-162

in vivo superfusion 154-155 spleen

PST 148,177 stereo selectivity

& PST 40 steroid

su1fation 87 su1fotransferase

heterogeneity 99 separation from PST 99

striatum DA

E

NE

free 147 sulfate 147

free 147 sulfate 147

free 147 sulfate 147

PST 147 sulfatase

& CA conjugation 175 sulfate

activation 133 ascites tumor uptake 133 administration 134 availability, for sulfation 127-144 brain uptake 131-133 & calcium availability 134 from cysteine 128 depletion 135-137 & diarrhea 129 & fasting 130 food sources 129-131 as laxative 129 & NMN uptake 49 & PAPS 127,137 pool size 127-129 from protein 128 RBC uptake 133 serum concentration 127,134

223

224 in man 134 in various species 128 & sulfation rate 137-140 uptake by tissues 131-133 urinary excretion 128 & various compounds, effect on sulfate conjugation 2-3

sulfation vs glucuronidation 87,88-89,135

in lung cancer tissue 119 of harmo1 88-89 inhibition, in vivo of large molecules rate

& sulfate levels su1fotransferases

Bi-Bi mechanism 38

86-97 86

138-139

distribution in animal kingdom 1 substrates 1

superfusates from eNS 152-163

taurine & cysteine administraq.on 134

thrombocytes ary1su1fatase 33,39 counting 31 MAO as marker 33 PST 39

toxification & conjugation enzymes 86-87

!!!.-tyramine as PST substrate 102,104 structure 104

E.-tyramine conjugation

in depression 192-197 & DA release 157-160 & platelet PST kinetics 106 & PST 45-46

from various tissues 107-108,110 as PST substrate 76,102,104,187-188

specificity 69 for various tissues 101

-sensitive migraine 145 structure 104 as sulfate acceptor

comparison with MHPG 24 & depression 40

tyrosine as PST substrate 103

"unconjugated hyperepinephrinemia" assay 180

vanillin as PST substrate 67

specificity 69 vanillyl alcohol

as PST substrate 67 specificity 69

ventricular fluid (also cf CSF) conjugated DA 164-174

ventriculo-·cisternal perfusion technique 153

225